Dyne Therapeutics, Inc. (DYN) — Stock Score Summary

Dyne Therapeutics, Inc. (DYN) has a MoatMap StockRank of 29/100 based on Quality (34/100), Value (37/100), and Momentum (45/100) factor scores. The current signal is SELL. Dyne Therapeutics is a clinical-stage biotech focused on muscle diseases. While its technology is promising, it is pre-revenue, highly speculative, and does not fit our quality compounder or CDMO pricing power themes.

Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing oligonucleotide therapeutics for rare, genetically driven muscle diseases. The company's proprietary FORCE (Fragment-based Oligonucleotide RNA-targeted Chimeric) platform is designed to overcome current delivery limitations, enabling precise targeting of muscle tissue. It operates as a specialized biotech firm, aiming to revolutionize treatment for conditions like myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD) through its innovative delivery technology.

Key Financial Metrics

Price$17.99
Market Cap$3.1B
P/E (Forward)-6.18
Price/Book3.12
Return on Equity-58.9%
Return on Invested Capital-38.7%
Debt/Equity19.50
Gross Margin0.0%
Operating Margin0.0%
Free Cash Flow$-292M

Dyne Therapeutics, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Dyne Therapeutics, Inc.’s (DYN) StockRank?
MoatMap’s StockRank for Dyne Therapeutics, Inc. (DYN) is 29/100, with a Sell signal. It is a composite of Quality (34), Value (37), and Momentum (45) factor ranks across MoatMap’s 19,000+ stock universe.
Does Dyne Therapeutics, Inc. have an economic moat?
Dyne Therapeutics, Inc. (DYN) has a Quality factor score of 34/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Dyne Therapeutics, Inc. a buy, hold, or sell?
MoatMap’s current signal for Dyne Therapeutics, Inc. (DYN) is Sell, based on a StockRank of 29/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Dyne Therapeutics, Inc. in?
Dyne Therapeutics, Inc. (DYN) operates in the Healthcare sector, specifically the Biotechnology industry (United States).
Browse all ranked stocksDYN deep dive reportAI ChampionsHow we score stocksSense-check another stock